Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2010 (2010), Article ID 573252, 3 pages
http://dx.doi.org/10.1155/2010/573252
Case Report

New Insights in the Management of Antipsychotics in the Treatment of Schizophrenia in a Patient with Prolactinoma: A Case Report and Review of the Literature

Psychiatry Department, Federal University of São Paulo (UNIFESP), 04023-900 São Paulo , Brazil

Received 21 July 2010; Accepted 21 October 2010

Academic Editor: Hitoshi Okamura

Copyright © 2010 Elvis Henrique Santos Andrade et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. F. Casanueva, M. E. Molitch, J. A. Schlechte et al., “Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas,” Clinical Endocrinology, vol. 65, no. 2, pp. 265–273, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. S. Melmed, “Update in pituitary disease,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 2, pp. 331–338, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. R. I. Holt, “Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists,” Journal of Psychopharmacology, vol. 22, no. 2, pp. 28–37, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. K. Melkersson and A.-L. Hulting, “Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder,” European Archives of Psychiatry and Clinical Neuroscience, vol. 250, no. 1, pp. 6–10, 2000. View at Google Scholar · View at Scopus
  5. S. Konopelska, M. Quinkler, C. J. Strasburger, and M. Ventz, “Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia—a case report with a review of the literature,” Journal of Clinical Psychopharmacology, vol. 28, no. 1, pp. 120–122, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. A. Abi-Dargham, “Do we still believe in the dopamine hypothesis? New data bring new evidence,” International Journal of Neuropsychopharmacology, vol. 7, no. 1, pp. S1–S5, 2004. View at Google Scholar · View at Scopus
  7. J. K. Pal and W. A. Sarino, “Effect of risperidone on prolactinoma growth in a psychotic woman,” Psychosomatic Medicine, vol. 62, no. 5, pp. 736–738, 2000. View at Google Scholar · View at Scopus
  8. C. Akkaya, B. Kaya, Z. Kotan, A. Sarandol, C. Ersoy, and S. Kirli, “Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases,” Journal of Psychopharmacology, vol. 23, no. 6, pp. 723–726, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. A. Farah, “Atypicality of atypical antipsychotics,” Primary Care Companion to the Journal of Clinical Psychiatry, vol. 7, no. 6, pp. 268–274, 2006. View at Google Scholar · View at Scopus
  10. R. L. Borison, L. A. Arvanitis, and B. G. Miller, “ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia,” Journal of Clinical Psychopharmacology, vol. 16, no. 2, pp. 158–169, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. R. S. Kahn, S. C. Schulz, V. D. Palazov et al., “Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study,” Journal of Clinical Psychiatry, vol. 68, no. 6, pp. 832–842, 2007. View at Google Scholar · View at Scopus